Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Tonix Pharmaceuticals Holding (TNXP) Return on Sales: 2024-2025

Historic Return on Sales for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to -9.52%.

  • Tonix Pharmaceuticals Holding's Return on Sales rose 304.00% to -9.52% in Q3 2025 from the same period last year, while for Sep 2025 it was -9.52%, marking a year-over-year increase of 304.00%. This contributed to the annual value of -13.54% for FY2024, which is 90.00% down from last year.
  • According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's Return on Sales is -9.52%, which was down 14.07% from -8.34% recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Return on Sales ranged from a high of -8.34% in Q2 2025 and a low of -13.57% during Q4 2024.
  • Moreover, its 2-year median value for Return on Sales was -12.46% (2024), whereas its average is -11.58%.
  • Data for Tonix Pharmaceuticals Holding's Return on Sales shows a peak YoY spiked of 401bps (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Tonix Pharmaceuticals Holding's Return on Sales stood at -13.57% in 2024, then soared by 304bps to -9.52% in 2025.
  • Its last three reported values are -9.52% in Q3 2025, -8.34% for Q2 2025, and -13.11% during Q1 2025.